GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Finch Therapeutics Group Inc (NAS:FNCH) » Definitions » Cash Flow from Investing

Finch Therapeutics Group (Finch Therapeutics Group) Cash Flow from Investing : $1.33 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Finch Therapeutics Group Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, Finch Therapeutics Group spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Finch Therapeutics Group gained $0.05 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


Finch Therapeutics Group Cash Flow from Investing Historical Data

The historical data trend for Finch Therapeutics Group's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Finch Therapeutics Group Cash Flow from Investing Chart

Finch Therapeutics Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
-0.97 -2.63 -15.92 -2.18 1.33

Finch Therapeutics Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.01 1.27 0.02 0.05

Finch Therapeutics Group Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Finch Therapeutics Group's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Finch Therapeutics Group's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Finch Therapeutics Group  (NAS:FNCH) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Finch Therapeutics Group's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Finch Therapeutics Group spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Finch Therapeutics Group's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Finch Therapeutics Group gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Finch Therapeutics Group's purchase of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Finch Therapeutics Group spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Finch Therapeutics Group's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Finch Therapeutics Group gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Finch Therapeutics Group's purchase of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Finch Therapeutics Group spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Finch Therapeutics Group's sale of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Finch Therapeutics Group gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Finch Therapeutics Group's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. It means Finch Therapeutics Group paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Finch Therapeutics Group's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.00 Mil. It means Finch Therapeutics Group paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Finch Therapeutics Group's cash from other investing activities for the three months ended in Dec. 2023 was $0.00 Mil. It means Finch Therapeutics Group paid $0.00 Mil for other investing activities.


Finch Therapeutics Group Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Finch Therapeutics Group's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Finch Therapeutics Group (Finch Therapeutics Group) Business Description

Traded in Other Exchanges
N/A
Address
200 Inner Belt Road, Suite 400, Somerville, MA, USA, 02143
Finch Therapeutics Group Inc is a clinical-stage microbiome therapeutics company. It is leveraging Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The lead product candidate is CP101 which delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection.
Executives
Jeffery A Smisek director 1600 SMITH STREET, HQSEO, HOUSTON TX 77002
Susan E Graf director 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Lance E Thibault officer: Chief Financial Officer
Matthew P. Blischak officer: Chief Executive Officer C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SOMERVILLE MA 02143
Joseph Vittiglio officer: Chief Business & Legal Officer C/O BLUEBIRD BIO, INC., 455 GRAND UNION BLVD, SOMERVILLE MA 02145
Marc Blaustein officer: Chief Operating Officer C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143
Domenic J Ferrante director BROOKSIDE CAPITAL MANAGEMENT LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Samuel A Hamood director C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661
Joanne L. Viney director C/O HARPOON THERAPEUTICS, INC., 131 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Nicholas Haft director C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143
Christian H. Lange director 28 HAVEMEYER PLACE, GREENWICH CT 06830
Crestovo Investor Llc director, 10 percent owner 28 HAVEMEYER PLACE, GREENWICH CT 06830
Gregory D Perry officer: Chief Financial Officer C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Chris Shumway director, 10 percent owner 28 HAVEMEYER PLACE, GREENWICH CT 06830
Zain Kassam officer: Chief Medical Officer C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143